TY - JOUR
T1 - Detection of influenza a/H1N1-specific human IgG-secreting B cells in older adults by elispot assay
AU - Painter, Scott D.
AU - Haralambieva, Iana H.
AU - Ovsyannikova, Inna G.
AU - Grill, Diane E.
AU - Poland, Gregory A.
PY - 2014/3/1
Y1 - 2014/3/1
N2 - B cells play an important role in humoral immunity and antibody production. Use of a B cell ELISPOT assay to quantify antigen-specific B cells can assist other assays to achieve a more complete profile of the humoral immune response after vaccination. We utilized a B cell ELISPOT assay to measure the number of influenza A/H1N1-specific B cells at key timepoints after seasonal influenza vaccination in 106 older adults (50-74 years of age). Blood was drawn from these subjects on Day 0, Day 3, Day 28, and Day 75 after vaccination to represent baseline, early, peak, and late response, respectively, of influenza A/H1N1-specific B cells. A significant increase in A/H1N1-specific B cells (median 36 spot-forming units/SFUs per 200,000 cells, p<0.0001) was seen on Day 28 compared to baseline and Day 3, and this number decreased (23 SFUs, p<0.0001) by Day 75, but not to baseline level. These data suggest that the B cell ELISPOT can be used to profile and monitor the humoral immune responses in older subjects after influenza vaccination, and serve as an immune signature marker.
AB - B cells play an important role in humoral immunity and antibody production. Use of a B cell ELISPOT assay to quantify antigen-specific B cells can assist other assays to achieve a more complete profile of the humoral immune response after vaccination. We utilized a B cell ELISPOT assay to measure the number of influenza A/H1N1-specific B cells at key timepoints after seasonal influenza vaccination in 106 older adults (50-74 years of age). Blood was drawn from these subjects on Day 0, Day 3, Day 28, and Day 75 after vaccination to represent baseline, early, peak, and late response, respectively, of influenza A/H1N1-specific B cells. A significant increase in A/H1N1-specific B cells (median 36 spot-forming units/SFUs per 200,000 cells, p<0.0001) was seen on Day 28 compared to baseline and Day 3, and this number decreased (23 SFUs, p<0.0001) by Day 75, but not to baseline level. These data suggest that the B cell ELISPOT can be used to profile and monitor the humoral immune responses in older subjects after influenza vaccination, and serve as an immune signature marker.
UR - http://www.scopus.com/inward/record.url?scp=84896760490&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896760490&partnerID=8YFLogxK
U2 - 10.1089/vim.2013.0099
DO - 10.1089/vim.2013.0099
M3 - Article
C2 - 24605786
AN - SCOPUS:84896760490
SN - 0882-8245
VL - 27
SP - 32
EP - 38
JO - Viral Immunology
JF - Viral Immunology
IS - 2
ER -